These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 33395287)
21. Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents. Ramesh R; Shingare RD; Kumar V; Anand A; B S; Veeraraghavan S; Viswanadha S; Ummanni R; Gokhale R; Srinivasa Reddy D Eur J Med Chem; 2016 Oct; 122():723-730. PubMed ID: 27476117 [TBL] [Abstract][Full Text] [Related]
22. Benzoheterocyclic Oxime Carbamates Active against van der Westhuyzen R; Mabhula A; Njaria PM; Müller R; Ngumbu Muhunga D; Taylor D; Lawrence N; Njoroge M; Brunschwig C; Moosa A; Singh V; Rao SPS; Manjunatha UH; Smith PW; Warner DF; Street LJ; Chibale K J Med Chem; 2021 Jul; 64(13):9444-9457. PubMed ID: 34138573 [TBL] [Abstract][Full Text] [Related]
23. MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target. Poce G; Consalvi S; Biava M Mini Rev Med Chem; 2016; 16(16):1274-1283. PubMed ID: 26776226 [TBL] [Abstract][Full Text] [Related]
24. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents. Lokesh BVS; Prasad YR; Shaik AB Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506 [TBL] [Abstract][Full Text] [Related]
25. Discovery and biological evaluation of an adamantyl-amide derivative with likely MmpL3 inhibitory activity. Kapp E; Calitz H; Streicher EM; Dippenaar A; Egieyeh S; Jordaan A; Warner DF; Joubert J; Malan SF; Sampson SL Tuberculosis (Edinb); 2023 Jul; 141():102350. PubMed ID: 37244249 [TBL] [Abstract][Full Text] [Related]
29. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA. Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D Bioorg Med Chem; 2014 Nov; 22(21):6134-45. PubMed ID: 25282650 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3. Li W; Obregón-Henao A; Wallach JB; North EJ; Lee RE; Gonzalez-Juarrero M; Schnappinger D; Jackson M Antimicrob Agents Chemother; 2016 Sep; 60(9):5198-207. PubMed ID: 27297488 [TBL] [Abstract][Full Text] [Related]
31. New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis. Giacobbo BC; Pissinate K; Rodrigues-Junior V; Villela AD; Grams ES; Abbadi BL; Subtil FT; Sperotto N; Trindade RV; Back DF; Campos MM; Basso LA; Machado P; Santos DS Eur J Med Chem; 2017 Jan; 126():491-501. PubMed ID: 27914363 [TBL] [Abstract][Full Text] [Related]
32. Structure-directed identification of pyridine-2-methylamine derivatives as MmpL3 inhibitors for use as antitubercular agents. Wen Y; Lun S; Jiao Y; Zhang W; Liu T; Yang F; Tang J; Bishai WR; Yu LF Eur J Med Chem; 2023 Jul; 255():115351. PubMed ID: 37116266 [TBL] [Abstract][Full Text] [Related]
33. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Li W; Upadhyay A; Fontes FL; North EJ; Wang Y; Crans DC; Grzegorzewicz AE; Jones V; Franzblau SG; Lee RE; Crick DC; Jackson M Antimicrob Agents Chemother; 2014 Nov; 58(11):6413-23. PubMed ID: 25136022 [TBL] [Abstract][Full Text] [Related]
34. Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis. Stec J; Vilchèze C; Lun S; Perryman AL; Wang X; Freundlich JS; Bishai W; Jacobs WR; Kozikowski AP ChemMedChem; 2014 Nov; 9(11):2528-37. PubMed ID: 25165007 [TBL] [Abstract][Full Text] [Related]
35. 6-hydrogen-8-methylquinolones active against replicating and non-replicating Mycobacterium tuberculosis. Tabarrini O; Sabatini S; Massari S; Pieroni M; Franzblau SG; Cecchetti V Chem Biol Drug Des; 2012 Nov; 80(5):781-6. PubMed ID: 22889240 [TBL] [Abstract][Full Text] [Related]
36. Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors: A Promising Approach to Combat Tuberculosis. Umare MD; Khedekar PB; Chikhale RV ChemMedChem; 2021 Oct; 16(20):3136-3148. PubMed ID: 34288519 [TBL] [Abstract][Full Text] [Related]
37. Identification of Mycobacterium tuberculosis CtpF as a target for designing new antituberculous compounds. Santos P; Lopez-Vallejo F; Ramírez D; Caballero J; Mata Espinosa D; Hernández-Pando R; Soto CY Bioorg Med Chem; 2020 Feb; 28(3):115256. PubMed ID: 31879181 [TBL] [Abstract][Full Text] [Related]
38. Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system. Bellale E; Naik M; V B V; Ambady A; Narayan A; Ravishankar S; Ramachandran V; Kaur P; McLaughlin R; Whiteaker J; Morayya S; Guptha S; Sharma S; Raichurkar A; Awasthy D; Achar V; Vachaspati P; Bandodkar B; Panda M; Chatterji M J Med Chem; 2014 Aug; 57(15):6572-82. PubMed ID: 24967731 [TBL] [Abstract][Full Text] [Related]